Macrocyclic Protease Inhibitor Synthesis via Diastereomeric Salt Resolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current processes for synthesizing the macrocyclic protease inhibitor of the hepatitis C virus (HCV) face challenges such as low yield, high complexity, and the need for cumbersome purification methods, particularly due to the use of chiral column chromatography, which is difficult to scale up and results in significant loss of undesired stereoisomeric forms.
Innovation Solution
A process is developed to prepare [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid] through selective resolution using brucine or ephedrine salts, avoiding chiral chromatography and enabling high enantiomeric purity without substantial loss of material, followed by cyclization to form the bicyclic lactone, a crucial intermediate in the synthesis of the macrocyclic inhibitor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chiral column chromatography is used for resolution, then enantiomeric purity is achieved, but the process becomes cumbersome and difficult to scale up with significant material loss
Solution Approach 1:
The patent uses brucine or ephedrine as intermediary substances to form diastereomeric salts with the racemic acid. These intermediaries enable selective crystallization of the desired enantiomer as a diastereomeric salt, which can then be purified by simple filtration and decomposed to yield the pure enantiomer. This intermediary approach replaces complex chiral chromatography with straightforward crystallization and decomposition steps.
Solution Approach 2:
The patent changes the physical-chemical parameters of the system by forming diastereomeric salts with different solubility characteristics. By selecting appropriate brucine or ephedrine salts and controlling crystallization conditions (temperature, solvent composition), the desired enantiomer can be selectively precipitated in high purity form, achieving enantiomeric separation without chromatography.
2Productivity
If conventional synthesis processes are used, then the macrocyclic inhibitor can be produced, but the yield is low and the synthesis is highly complex
Solution Approach 1:
The patent performs preliminary enantiomeric resolution at an early stage in the synthesis pathway, before proceeding to subsequent cyclization and macrocyclization steps. By resolving the racemic acid to the desired enantiomer first, all subsequent reactions proceed with high stereoselectivity, avoiding the need for complex chiral control measures later in the synthesis and improving overall yield.
Solution Approach 2:
The patent divides the synthesis into distinct modular segments: (1) resolution of racemic acid using brucine/ephedrine salts, (2) cyclization to form the bicyclic lactone, and (3) macrocyclization to form the final inhibitor. This segmentation allows each step to be optimized independently and simplifies the overall synthetic route by eliminating the need for complex chiral auxiliaries in later steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for high-yield production of the macrocyclic inhibitor with high stereochemical purity, simplifying the synthesis and eliminating the need for cumbersome purification steps, making it suitable for large-scale production.
Implementation Method 1
reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-(-)-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-(-)-ephedrine salt of (V), and precipitating selectively the bis-brucine or bis-(1R,2S)-(-)-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid (II)
Data Source
AI summary
A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-(-)- ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-(-)-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-(-)-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis- (1R,2S)-(-)-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-(-)-ephedrine from the precipitated salt obtained in step (b).